

Special Issue

Human Papillomavirus and Cancers

Message from the Guest Editors

The human papillomaviruses (HPV) are the major cause of nearly all cervical cancers and of a significant fraction of several other human malignancies arising from the mucosal squamous epithelia of anus, vagina, vulva, penis, and oropharynx. Despite the great long-term promise of HPV vaccination for the global prevention of cervical cancer, HPV-related cancers will remain a major health problem for decades to come. The long-term persistent infection, and the constitutive expression of HPV oncoproteins cause the accumulation of genetic and epigenetic alterations in the infected cells leading to cancer development and progression. Welcome Review and Research Articles that cover any relevant topic on the molecular mechanisms that contribute to HPV-induced carcinogenesis, including the role of oncoviral proteins in cell transformation, the gene mutational profile of viral and host genomes, expression levels of miRNAs, gene methylation, immune response, and new therapeutic opportunities including cancer vaccines for HPV-related cancers.

Guest Editors

Dr. Maria Lina Tornesello

Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, 80131 Napoli, Italy

Dr. Franco M. Buonaguro

Molecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy

Deadline for manuscript submissions

closed (31 July 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/24873

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)